不同剂量促红细胞生成素对于早产儿神经发育的作用

目的 探讨不同剂量促红细胞生成素(rhEPO),对早产儿神经系统发育的影响。方法 入住本院NICU病房的早产儿, 按入院先后次序分为rhEPO组(治疗组)和对照组,其中治疗组120例,对照组30例,其中rhEPO治疗组又随机分为3组,低剂量组(750 U·周·kg^-1),中等剂量组(1 500 U·周·kg^-1),高剂量组2 000 U·周·kg^-1)。比较2组早产儿在纠正胎龄40周时的新生儿神经行为测定(NBNA)评分和6,12月时的Gesell发育量表的评估得分。结果 rhEPO组NBNA评分显著高于对照组,中等剂量和高剂量组分别优于低剂量组(P<0.05),中等剂量和高剂量组无明显差异; 生后6个月时rhEPO组优于对照组大运动和适应能力,12个月时大运动、语言能力及精细动作得分实验组亦高于对照组(P<0.05)。结论 早期使用大剂量 EPO可显著改善早产儿预后,促进其神经系统发育。

Different doses of erythropoietin protect neural development in premature infant

ObjectiveThis study of rhEPO treatment in premature, observe whether rhEPO has influence to the development of the nervous system in premature infants, and the effect of different doses have differences.Methods In our NICU ward of premature infants. According to admission order divided into rhEPO treatment group and control group, the treatmentgroup 120 cases, control group 30 cases, Including rhEPO treatment group was randomly divided into three groups, low doses of 750 u·W ^{- 1}·kg^{- 1}, medium dose of 1 500 u·W ^{- 1} kg^-1, high dose of2 000 u·W ^{- 1} kg^-1. Compare two groups of premature infants in the correct determination of neonatalneurobehavioral gestational age at 40 weeks(NBNA)scores and 6 and 12 months of Gesell developmental scale assessment score.Results RhEPO group's NBNA score significantly higher than that of control group, Moderate dose and high dose group's score higher than the low dose group, middle dose and high dose group, no difference; treatment group after 6, 12 months for two groups of children with evaluation of Gesell developmental scale, 6 months big movement and the ability to adapt the experimental group is better than that of control group, 12 months big movement, language and fine motor score of experimental group is higher than that of control group, compared to similar between the two groups have statistical significance.Conclusion The early use of large dose of rhEPO can significantly improve the prognosis of premature infants, promote the development of the nervous system.